This page has not been authorized, sponsored, or otherwise approved or endorsed by the companies represented herein. Each of the company logos represented herein are trademarks of Microsoft Corporation; Dow Jones & Company; Nasdaq, Inc.; Forbes Media, LLC; Investor's Business Daily, Inc.; and Morningstar, Inc.
Copyright 2025 Zacks Investment Research | 101 N Wacker Drive, Floor 15, Chicago, IL 60606
At the center of everything we do is a strong commitment to independent research and sharing its profitable discoveries with investors. This dedication to giving investors a trading advantage led to the creation of our proven Zacks Rank stock-rating system. Since 1988 it has more than doubled the S&P 500 with an average gain of +23.75% per year. These returns cover a period from January 1, 1988 through July 7, 2025. Zacks Rank stock-rating system returns are computed monthly based on the beginning of the month and end of the month Zacks Rank stock prices plus any dividends received during that particular month. A simple, equally-weighted average return of all Zacks Rank stocks is calculated to determine the monthly return. The monthly returns are then compounded to arrive at the annual return. Only Zacks Rank stocks included in Zacks hypothetical portfolios at the beginning of each month are included in the return calculations. Zacks Ranks stocks can, and often do, change throughout the month. Certain Zacks Rank stocks for which no month-end price was available, pricing information was not collected, or for certain other reasons have been excluded from these return calculations. Zacks may license the Zacks Mutual Fund rating provided herein to third parties, including but not limited to the issuer.
Visit Performance Disclosure for information about the performance numbers displayed above.
Visit www.zacksdata.com to get our data and content for your mobile app or website.
Real time prices by BATS. Delayed quotes by Sungard.
NYSE and AMEX data is at least 20 minutes delayed. NASDAQ data is at least 15 minutes delayed.
This site is protected by reCAPTCHA and the Google Privacy Policy, DMCA Policy and Terms of Service apply.
View All Zacks #1 Ranked Stocks
Zacks News
Align Technology, based in California, manufactures and markets a system of clear aligner therapy, intra-oral scanners and CAD/CAM (computer-aided design and computer-aided manufacturing) digital services used in dentistry, orthodontics, and dental records storage. The clear aligner system corrects malocclusion using nearly invisible and removable appliances that gently move the tooth to a desired final position.
Align Technology (ALGN) Earnings Expected to Grow: Should You Buy?
by Zacks Equity Research
Align Technology (ALGN) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
Here's Why You Should Add Cencora (COR) to Your Portfolio Now
by Zacks Equity Research
Cencora (COR) continues to gain traction from the robust U.S. Healthcare Solutions segment. However, stiff competition is a woe.
STERIS' (STE) Improved Volume, New Buyouts Drive Growth
by Zacks Equity Research
On the capital equipment side for STERIS (STE), the easing of supply-chain issues and reduced lead times are boosting shipments.
PetMeds (PETS) to Advance Pet Care With New Collaboration
by Zacks Equity Research
PetMeds (PETS) is positioning itself more firmly in the field of pet health and wellness as a result of its established reputation in the pet pharmaceutical industry.
Orthofix (OFIX) Secures FDA 510k Clearance for OsteoCove Graft
by Zacks Equity Research
Orthofix (OFIX) announces the full commercial availability of the OsteoCove synthetic graft after gaining the FDA's nod.
Here's Why You Should Buy Edward Lifesciences (EW) Stock Now
by Zacks Equity Research
Investors remain optimistic about Edward Lifesciences (EW) on the strength of the Critical Care business and TAVR sales.
Here's Why You Should Invest in Insulet (PODD) Stock for Now
by Zacks Equity Research
Investors are optimistic about Insulet (PODD) on continued expansion in Omnipod's market access.
Alcon (ALC) Stock Up 9.7% YTD: Will the Rally Continue?
by Zacks Equity Research
Alcon (ALC) continues gaining from the company's diverse portfolio, incremental innovation, and new product launches.
Is Align Technology (ALGN) Outperforming Other Medical Stocks This Year?
by Zacks Equity Research
Here is how Align Technology (ALGN) and Artivion (AORT) have performed compared to their sector so far this year.
Boston Scientific's (BSX) Wavewriter Alpha SCS Gets FDA's Nod
by Zacks Equity Research
Boston Scientific (BSX) receives the FDA's nod for an expanded indication of Wavewriter SCS Systems.
Here's Why Investors Should Retain Thermo Fisher (TMO) Stock
by Zacks Equity Research
Investors continue to be optimistic about Thermo Fisher (TMO) due to its impressive acquisition deals and end-market strength.
Here's Why You Should Retain Fresenius Medical (FMS) for Now
by Zacks Equity Research
Fresenius Medical (FMS) continues to gain traction through its broad dialysis product and service portfolio. Intense competition is a woe.
Masimo (MASI) Gets De Novo for Novel Oxygen Status Index ORi
by Zacks Equity Research
Masimo's (MASI) ORi parameter gets De Novo from the FDA, providing option for continuous monitoring of oxygen level in surgical patients leading to better management of hyperoxia.
Teleflex (TFX) Advances Urology Portfolio With New Buyout
by Zacks Equity Research
Teleflex's (TFX) recent buyout is in line with its strategy of acquiring assets that accelerate the rate of expansion.
Globus Medical (GMED) Gains From NuVasive Buyout, Innovation
by Zacks Equity Research
Globus Medical (GMED) is particularly seeing notable gains across its product portfolio in expandables, biologics, MIS screws, 3D printed implants and cervical offerings.
Labcorp (LH) Launches Biomarker Test for Alzheimer's Disease
by Zacks Equity Research
Labcorp's (LH) new test, ATN Profile, is likely to accelerate the path to the diagnosis of Alzheimer's disease.
5 Large-Cap Stocks to Buy on the Dip for Q4 2023
by Nalak Das
We have narrowed our search to five large-cap (market capital > $10 billion) stocks with attractive valuations. These stocks are: TWLO, KDP, ULTA, ALGN, ZBH.
Reasons to Retain The Cooper Companies (COO) in Your Portfolio
by Zacks Equity Research
The Cooper Companies (COO) benefits from strength in its business segments. Its acquisitions are likely to drive the top line. A rise in selling, general and administrative expenses is concerning.
Fresenius Medical (FMS) Sinks on Potential Rise in Competition
by Zacks Equity Research
Fresenius Medical's (FMS) shares decline more than 17% on Wednesday following news of the successful clinical trial of a competing drug in preventing kidney disease.
Alcon (ALC) Gains From Growing Market Demand, New Launches
by Zacks Equity Research
Within Vision Care, Alcon (ALC) is registering solid growth, banking on strong sales of its contact lenses and ocular health products.
ZimVie (ZIMV) Progresses in Dental Space With Biotivity Launch
by Zacks Equity Research
ZimVie's (ZIMV) Biotivity A/C Plus Membrane is a barrier membrane that contains an array of growth factors.
Walgreens Boots (WBA) Q4 Earnings Miss Estimates, Margins Down
by Zacks Equity Research
Walgreens Boots (WBA) Q4 retail revenues are impacted by macroeconomic-driven consumer pressure and lower COVID-19 OTC test kit sales.
Here's Why You Should Hold on to Penumbra (PEN) Stock for Now
by Zacks Equity Research
Investors are optimistic about Penumbra (PEN), driven by strong vascular and neuro businesses.
Hologic (HOLX) to Elevate OB-GYN Training With New Partnerships
by Zacks Equity Research
Hologic's (HOLX) collaboration with AAGL and Inovus Medical is likely to optimize OB-GYN training for minimally invasive surgeries.
Here's Why Investors Should Buy Bruker (BRKR) Stock Now
by Zacks Equity Research
The strong prospects of the BSI BioSpin and CALID group are likely to bode well for Bruker (BRKR) stock.